Novartis slightly misses Q3 net sales estimates, but tops core EPS view

Novartis AG

27/10/2026 06:11

Overview
Switzerland's innovative medicines firm Q3 net sales grew 4% but slightly missed analyst expectations
Core EPS rose 9%, beating analysts' expectations
Quarterly sales growth driven by strong performance of priority brands Kisqali, Kesimpta, Scemblix

Outlook
Novartis expects 2026 net sales to grow low single-digit
Company ups 2026 core operating income forecast to in-line to growing low single-digit from a low-single-digit decline
Foreign exchange expected to add 1 percentage point to 2026 net sales and core operating income

Result Drivers
PRIORITY BRANDS - Co said Q3 sales growth was driven by strong performance of Kisqali, Kesimpta, Scemblix, Leqvio and Cosentyx
VOLUME GROWTH OFFSET BY GENERICS - Co said Q3 net sales benefited from volume growth, partly offset by generic competition and negative pricing impact
PRODUCTIVITY EFFORTS - Co said productivity initiatives contributed to improved core operating income and margin

Company press release: ID:nGNE8KBVks

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Sales
Slight Miss*
$14.52 bln
$14.58 bln (13 Analysts)
Q3 Core EPS
Beat
$2.46
$2.27 (12 Analysts)
Q3 EPS
 
$0.63
 
Q3 Core Net Income
 
$4.66 bln
 
Q3 Net Income
 
$1.20 bln
 
Q3 Core Operating Income
 
$6.04 bln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy", 15 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Novartis AG is CHF125.90, about 1.2% below its October 26 closing price of CHF127.48
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
Oct 25 - Roche says divarasib cut risk of death 44% in lung cancer trial
Oct 26 - China's WuXi AppTec nine-month revenue rises on chemistry segment growth; lifts 2026 outlook
Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)